Daclizumab

Last updated
Daclizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD25
Clinical data
Trade names Zinbryta (multiple sclerosis)
Zenapax (acute transplant rejection, discontinued in 2009)
AHFS/Drugs.com zinbryta
Pregnancy
category
  • AU:B3
Routes of
administration 		Subcutaneous injection, Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 90%
Metabolism Proteases
Elimination half-life 21 days (11–38 days)
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C6332H9808N1678O1989S42
Molar mass 142612.39 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

Contents

In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe. [4] [5] [3]

Medical uses

Daclizumab was used to treat adults with relapsing forms of multiple sclerosis. [6] It is administered subcutaneously. [7]

In clinical trials, decreases of 45% in annualized relapse rate have been reported, as well as a 41% reduction in the proportion of patients who relapsed, and a 54% reduction in the number of new lesions. [7] A 2013 Cochrane systematic review concluded that there was insufficient evidence to determine the efficacy of daclizumab relative to placebo in people with relapsing-remitting MS and, prior to its being discontinued, the need to investigate longer lengths of treatment and follow-up. [8]

Discontinued use

Daclizumab was approved and used to prevent acute rejection of kidney transplant, along with cyclosporine and corticosteroids. [9] For that indication, side effects with a frequency of at least 10% included sleeplessness, tremor, headache, arterial hypertension, dyspnoea, gastrointestinal side effects and oedema. In rare cases, the drug could cause severe anaphylaxis. [10]

Contraindications

In the US, daclizumab (while approved) was contraindicated in people with liver impairment, including significantly elevated liver enzymes (ALT, AST) and autoimmune hepatitis. [11]

The European Medicines Agency (EMA) originally approved the drug without any contraindications apart from known hypersensitivity, [12] but required Biogen to implement a hepatic risk management guide for physicians. [13] In July 2017, the EMA has issued a provisional contraindication for patients with pre-existing liver disease or liver impairment. [14] The marketing authorisation was withdrawn in the EU on 27 March 2018. An EMA review concluded that the medicine poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs. [15]

Adverse effects

In clinical trials for MS, there were no treatment-related deaths or increased risk of cancer; side effects that occurred more frequently with daclizumab versus interferon included infections (65% versus 57%), skin rashes (37% versus 19%) and liver complications (approximately 18% versus 12%). [7]

Interactions

As an antibody, daclizumab is expected to have a very low potential for pharmacokinetic interactions with other drugs. [12]

Pharmacology

Mechanism of action

Daclizumab blocks IL-2 receptors containing the alpha subunit (CD25), which include the high-affinity receptors. Medium-affinity receptors, on the other hand, consist of two beta subunits (CD122) and are not affected by daclizumab. While the exact mechanism is unknown, the net effect is a reduction of T-cell responses and expansion of CD56 bright natural killer cells. [12]

Pharmacokinetics

After subcutaneous injection of a single dose, daclizumab has a bioavailability of about 90% and reaches highest blood plasma levels after 5 to 7 days. Given every four weeks, steady state concentrations are found after the fourth dose. It is expected that daclizumab, like other antibodies, is degraded by proteases to peptides and finally amino acids, and that it does not interact with cytochrome P450 liver enzymes. [12]

The biological half-life is 21 days. Patients who developed antibodies against daclizumab eliminated it 19% faster. [12]

History

Daclizumab was created by scientists at PDL BioPharma (called "Protein Design Labs" at that time) by humanizing the mouse mAb called anti-Tac, which targets CD25, the IL-2 receptor α chain; it blocks the interaction of IL-2 with the IL-2 receptor and prevents activation of T cells. [16] Anti-Tac had been discovered by Thomas A. Waldmann, M.D., chief of the Metabolism Branch at the National Cancer Institute and his team, and they had conducted animal studies and a small clinical trial of anti-Tac in people with T-cell leukemia, with promising results, but people quickly developed their own antibodies rejecting the mouse protein; Waldman, and his colleagues then approached Protein Design Labs to humanize the antibody. [17] PDL and the NIH scientists then approached Roche, a leader in transplant medicine development, to get the drug developed and approved, as PDL didn't have the resources to actually bring the product to market. [17] In March 2018 the drug was removed from the market worldwide.

In December 1997 daclizumab was approved by the FDA for use in preventing acute rejection of kidney transplants, in combination with ciclosporin and corticosteroids; it was the first humanized antibody approved anywhere in the world. [18] [19] At launch, the average wholesale price for the drug was estimated to be $6,800 for five doses and it was estimated that annual sales would be between $100 million and $250 million within five years of the launch and it was thought that the drug's use would be expanded for use in other organ transplants. [19] It was approved in Europe in 1999. [20]

PDL began clinical trials of daclizumab on its own, and in September 2004 after the drug had shown promise in a Phase II trial, PDL and Roche agreed to expand their relationship to include codevelopment of daclizumab for asthma and other respiratory conditions. [21] In August 2005, PDL and Biogen Idec agreed to collaborate to develop daclizumab in indications outside the fields of organ rejection and respiratory disease. [22] In November 2005 Roche and PDL agreed to try to develop a formulation of daclizumab that would be useful as a subcutaneous injection for longterm maintenance in organ transplant. [23] The next year Roche and PDL announced that the collaboration for all indications was ending, [24] and in 2009 it announced that it was discontinuing Zenapax worldwide "in view of available alternative treatments and the diminishing market demand" and "not due to any safety issue." [25] [26]

in 2008 PDL spun out its active development programs into a company called Facet Biotech and development of daclizumab for multiple sclerosis and the partnership with Biogen was included in that spinout. [27] [28] In 2009 Biogen attempted a hostile buy out of Facet for $350M; [29] Facet rejected that offer and was purchased by Abbvie for $450 million in cash the next year. [30] In May 2016 the FDA approved daclizumab for the treatment of relapsing multiple sclerosis in adults in 2016 under the trade name Zinbryta, with requirements for postmarketing studies and to submit a formal Risk Evaluation and Mitigation Strategy. [6] [31]

Research

Daclizumab has been studied in a small clinical trial of people with birdshot chorioretinopathy. [32]

Related Research Articles

<span class="mw-page-title-main">Immunosuppressive drug</span> Drug that inhibits activity of immune system

Immunosuppressive drugs, also known as immunosuppressive agents, immunosuppressants and antirejection medications, are drugs that inhibit or prevent the activity of the immune system.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Interferon beta-1a</span> Cytokine in the interferon family

Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses.

Basiliximab, sold under the brand name Simulect, is a monoclonal antibody used to prevent rejection in kidney transplants. It is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used in combination with other medicines used to prevent organ rejection.

<span class="mw-page-title-main">Natalizumab</span> Medication used to treat multiple sclerosis and Crohns disease

Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier.

<span class="mw-page-title-main">Alemtuzumab</span> Medication

Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. It is given by injection into a vein.

Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis. It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds. It is administered by intravenous infusion. The fixed-dose combination ocrelizumab/hyaluronidase is administered by subcutaneous injection.

Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. Tocilizumab was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.

Visilizumab is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease.

Teplizumab, sold under the brand name Tzield, is a humanized anti-CD3 monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D.

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US.

<span class="mw-page-title-main">Dimethyl fumarate</span> Chemical compound

Dimethyl fumarate (DMF) is the methyl ester of fumaric acid and is named after the earth smoke plant. Dimethyl fumarate combined with three other fumaric acid esters (FAEs) is solely licensed in Germany as an oral therapy for psoriasis. Since 2013, it has been approved by the U.S. Food and Drug Administration (FDA) as a treatment option for adults with relapsing multiple sclerosis. In 2017, an oral formulation of dimethyl fumarate was approved for medical use in the European Union as a treatment for moderate-to-severe plaque psoriasis. Dimethyl fumarate is thought to have immunomodulatory properties without causing significant immunosuppression.

Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer. It was originated by GlycArt Biotechnology AG and developed by Roche.

MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate used for the treatment of urothelial cancer. It is a nectin-4-directed antibody and microtubule inhibitor conjugate. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.

<span class="mw-page-title-main">Ozanimod</span> Medication

Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. It acts as a sphingosine-1-phosphate receptor (S1PR) agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.

PDL BioPharma is a publicly traded American holding company that since 2008 manages patents and other intellectual property that had been generated by the company. In 2008 in response to shareholder pressure, PDL spun out its active development programs to a company called Facet Biotech that it capitalized with $400 million.

There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market.

Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.

<span class="mw-page-title-main">Thomas A. Waldmann</span> American immunologist (1930–2021)

Thomas A. Waldmann was an American immunologist who has worked on therapeutic monoclonal antibodies to the IL-2 receptor, Interleukin 15 (IL-15), and Adult T-cell Leukemia (ATL). Until the week he died, he was an active distinguished investigator at the Lymphoid Malignancies Branch of the National Cancer Institute.

References

  1. ↑ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  2. ↑ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada . 14 March 2017. Retrieved 7 April 2024.
  3. 1 2 "FDA working with manufacturers to withdraw Zinbryta from the market in the United States". U.S. Food and Drug Administration (FDA). Retrieved 15 March 2018.
  4. ↑ "Biogen, AbbVie withdraw multiple sclerosis drug Zinbryta". Reuters. 2018.
  5. ↑ Loftus P (2 March 2018). "Biogen and Abbvie Take Multiple Sclerosis Drug Off Market". The Wall Street Journal.
  6. 1 2 FDA "BLA Approval letter" (PDF). U.S. Food and Drug Administration. 27 May 2016.
  7. 1 2 3 Lycke J (November 2015). "Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes". Therapeutic Advances in Neurological Disorders. 8 (6): 274–293. doi:10.1177/1756285615605429. PMC   4643868 . PMID   26600872.
  8. ↑ Liu J, Wang LN, Zhan S, Xia Y (December 2013). "Daclizumab for relapsing remitting multiple sclerosis". The Cochrane Database of Systematic Reviews (12): CD008127. doi:10.1002/14651858.CD008127.pub4. PMC   11491876 . PMID   24363032.
  9. ↑ "Rejection label Supplement label update" (PDF). U.S. Food and Drug Administration. September 2005.
  10. ↑ "EPAR for Zenapax" (PDF). European Medicines Agency. 2007.[ permanent dead link ]
  11. ↑ FDA Professional Drug Information for Zinbryta.
  12. 1 2 3 4 5 Haberfeld, H, ed. (2016). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.
  13. ↑ "Zinbryta Summary of Product Characteristics" (PDF). European Medicines Agency. 2016. Archived from the original (PDF) on 2018-06-14. Retrieved 2016-12-09.
  14. ↑ "Zinbryta Article-20 referral - Summary of provisional measures" (PDF). European Medicines Agency. 20 July 2017. Archived from the original (PDF) on 24 July 2018. Retrieved 21 July 2017.
  15. ↑ "EMA review of Zinbryta confirms medicine's risks outweigh its benefits". European Medicines Agency. 27 March 2018.
  16. ↑ Tsurushita N, Hinton PR, Kumar S (May 2005). "Design of humanized antibodies: from anti-Tac to Zenapax". Methods. 36 (1): 69–83. doi:10.1016/j.ymeth.2005.01.007. PMID   15848076.
  17. 1 2 Swenson RS, Weisinger JR, Ruggeri JL, Reaven GM (February 1975). "Evidence that parathyroid hormone is not required for phosphate homeostasis in renal failure". Metabolism. 24 (2): 199–204. doi:10.1016/0026-0495(75)90021-9. PMID   1113683.
  18. ↑ Fisher LM (12 December 1997). "Genetically Engineered Drug Approved for Kidney Transplants". The New York Times.
  19. 1 2 "Roche's Zenapax Gets First Approval For Transplants". The Pharma Letter. 17 December 1997.
  20. ↑ "Zenapax (daclizumab), The First Humanized Monoclonal Antibody To Prevent Organ Rejection, Approved In The European Union". Roche Press Release. 4 March 1999. Archived from the original on 28 August 2021. Retrieved 1 June 2016.
  21. ↑ Hoffmann C (16 September 2004). "Roche in new deal to co-development asthma drug". First Word Pharma.
  22. ↑ Thiel KA (October 2005). "A very firm handshake: biotech's growing negotiating power". Nature Biotechnology. 23 (10): 1221–1226. doi:10.1038/nbt1005-1221. PMID   16211058. S2CID   19365410.
  23. ↑ "Roche inks new deal for transplant drug". PharmaTimes. 1 November 2005.
  24. ↑ "Roche ducks out of transplant drug alliance". PharmaTimes. 23 November 2006.
  25. ↑ "EMEA: Withdrawal of the marketing authorisation in the European Union" (PDF). Archived from the original (PDF) on 2010-02-17. Retrieved 2010-03-11.
  26. ↑ "Letter to Healthcare Professionals" (PDF). Roche. U.S. Food and Drug Administration. September 2009.
  27. ↑ Carroll J. "Emerging Drug Developer: Facet Biotech". FierceBiotech.
  28. ↑ "PDL BioPharma, Inc. Form 8-K". 17 December 2008.
  29. ↑ Timmerman L (4 September 2009). "Biogen Idec Makes Hostile $350M Takeover Bid for Facet Biotech". Xconomy.
  30. ↑ "Abbott to Buy Facet Biotech for 67% Premium". New York Times Dealbook. 9 March 2010.
  31. ↑ "FDA approves Zinbryta to treat multiple sclerosis". FDA News Release. U.S. Food and Drug Administration. 27 May 2016.
  32. ↑ Sobrin L, Huang JJ, Christen W, Kafkala C, Choopong P, Foster CS (February 2008). "Daclizumab for treatment of birdshot chorioretinopathy". Archives of Ophthalmology. 126 (2): 186–191. doi:10.1001/archophthalmol.2007.49. PMID   18268208.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.